Mobile

A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 μg and 240 μg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children a...

Update Il y a 5 ans
Reference: EUCTR2004-000593-32

A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 μg and 240 μg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the preference of subjects for Minirin® oral lyophilisate treatment compared with Minirin® tablet treatment after 6 weeks.

Inclusion criteria

  • Primary Nocturnal Enuresis

Links